BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 15848544)

  • 21. Use of basiliximab and cyclosporine in heart transplant patients with pre-operative renal dysfunction.
    Delgado DH; Miriuka SG; Cusimano RJ; Feindel C; Rao V; Ross HJ
    J Heart Lung Transplant; 2005 Feb; 24(2):166-9. PubMed ID: 15701432
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of alemtuzumab vs. antithymocyte globulin induction therapy in primary non-sensitized renal transplant patients treated with rapid steroid withdrawal.
    Saull HE; Enderby CY; Gonwa TA; Wadei HM
    Clin Transplant; 2015 Jul; 29(7):573-80. PubMed ID: 25711849
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.
    Farney AC; Doares W; Rogers J; Singh R; Hartmann E; Hart L; Ashcraft E; Reeves-Daniels A; Gautreaux M; Iskandar SS; Moore P; Adams PL; Stratta RJ
    Transplantation; 2009 Sep; 88(6):810-9. PubMed ID: 19920781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BK virus-associated nephropathy in sirolimus-treated renal transplant patients: incidence, course, and clinical outcomes.
    Benavides CA; Pollard VB; Mauiyyedi S; Podder H; Knight R; Kahan BD
    Transplantation; 2007 Jul; 84(1):83-8. PubMed ID: 17627242
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Basiliximab-sirolimus-prednisone induction regimen followed by delayed low-dose cyclosporine in renal transplant recipients of living donors.
    Langer RM; Hong DM; Katz SM; Van Buren CT
    Transplant Proc; 2002 Dec; 34(8):3162-4. PubMed ID: 12493406
    [No Abstract]   [Full Text] [Related]  

  • 26. Assessment of immunosuppression induction with basiliximab compared to antithymocyte-globulin in adult heart transplant patients.
    Eberhardt TE; Kim DH; Nethersole S; Pearson GJ
    Clin Transplant; 2024 Jun; 38(6):e15332. PubMed ID: 38804609
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Basiliximab combined with low-dose rabbit anti-human thymocyte globulin: a possible further step toward effective and minimally toxic T cell-targeted therapy in kidney transplantation.
    Ruggenenti P; Codreanu I; Cravedi P; Perna A; Gotti E; Remuzzi G
    Clin J Am Soc Nephrol; 2006 May; 1(3):546-54. PubMed ID: 17699258
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of extended-duration inpatient-to-outpatient rabbit antithymocyte globulin induction in de novo kidney transplant recipients: 6-month outcomes.
    Trofe-Clark J; Reese PP; Patel HJ; Jakobowski D; Goral S; Doll SL; Abt PL; Bloom RD
    Transplantation; 2012 Sep; 94(5):506-12. PubMed ID: 22895613
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
    Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
    Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sequential quadruple immunosuppression including sirolimus in extended criteria and nonheartbeating donor kidney transplantation.
    Diekmann F; Campistol JM; Saval N; Gutiérrez-Dalmau A; Arellano EM; Crespo M; Rossich E; Esforzado N; Cofán F; Ricart MJ; Torregrosa JV; Oppenheimer F
    Transplantation; 2007 Aug; 84(3):429-32. PubMed ID: 17700171
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Repeat renal allografts treated with sirolimus, cyclosporine, anti-thymocyte globulin induction and continuous steroids achieve similar immunosuppressive efficacy as primary transplants.
    Petero VG; Kaposztas Z; Kahan BD
    Clin Transplant; 2010; 24(2):243-51. PubMed ID: 19694771
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction treatment with low-dose thymoglobulin or basiliximab in renal transplants from older donors.
    Gavela Martínez E; Sancho Calabuig A; Escudero Quesada V; Avila Bernabeu AI; Beltrán Catalán S; Morales García AI; Crespo Albiach JF; Pallardó Mateu LM
    Transplant Proc; 2008 Nov; 40(9):2900-2. PubMed ID: 19010141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 5-year results of a prospective, randomized, single-center study of alemtuzumab compared with rabbit antithymocyte globulin induction in simultaneous kidney-pancreas transplantation.
    Stratta RJ; Rogers J; Orlando G; Farooq U; Al-Shraideh Y; Farney AC
    Transplant Proc; 2014; 46(6):1928-31. PubMed ID: 25131073
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen.
    Yang SL; Wang D; Wu WZ; Lin WH; Xu TZ; Cai JQ; Tan JM
    Transpl Immunol; 2008 Jan; 18(3):281-5. PubMed ID: 18047938
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rabbit antithymocyte globulin induction therapy in adult renal transplantation.
    Hardinger KL
    Pharmacotherapy; 2006 Dec; 26(12):1771-83. PubMed ID: 17125438
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of terminal complement blockade on the efficacy of induction with polyclonal rabbit antithymocyte globulin in living donor renal allografts.
    Goh BK; Chedid MF; Gloor JM; Raghavaiah S; Stegall MD
    Transpl Immunol; 2012 Oct; 27(2-3):95-100. PubMed ID: 22813834
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduced dose rabbit anti-thymocyte globulin induction for prevention of acute rejection in high-risk kidney transplant recipients.
    Klem P; Cooper JE; Weiss AS; Gralla J; Owen P; Chan L; Wiseman AC
    Transplantation; 2009 Oct; 88(7):891-6. PubMed ID: 19935460
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Thymoglobulin dose optimization for induction therapy in high risk kidney transplant recipients.
    Gurk-Turner C; Airee R; Philosophe B; Kukuruga D; Drachenberg C; Haririan A
    Transplantation; 2008 May; 85(10):1425-30. PubMed ID: 18497682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Excellent renal allograft survival in donor-specific antibody positive transplant patients-role of intravenous immunoglobulin and rabbit antithymocyte globulin.
    Mai ML; Ahsan N; Wadei HM; Genco PV; Geiger XJ; Willingham DL; Taner CB; Hewitt WR; Grewal HP; Nguyen JH; Hughes CB; Gonwa TA
    Transplantation; 2009 Jan; 87(2):227-32. PubMed ID: 19155977
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of induction based on continuous vs discontinuous administration of antithymocyte globulins in renal transplant patients: efficacy and long-term safety.
    Esposito L; Kamar N; Durand D; Rostaing L
    Transplant Proc; 2005 Mar; 37(2):892-4. PubMed ID: 15848567
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.